Harrison W. Farber, MD
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, George Washington University

Dr. Farber is considered an opinion leader and internationally recognized expert in the field of pulmonary hypertension. He is a Professor in the Department of Medicine and attends in the Medical Intensive Care Unit and on the Pulmonary Consultation Service at Boston Medical Center. He also oversees the care of all patients with Pulmonary Hypertension at Boston Medical Center.

Dr. Farber’s research focuses on endothelial cell biology, in particular, the response of the pulmonary vasculature to injury. He has extensive government and private funding and is an NIH-funded Principle Investigator on several grants. He is a member of several research groups both within the Pulmonary Center and in other divisions within the Department of Medicine: the Pulmonary Vascular Biology Group (Pulmonary Center); the Center for Excellence in Sickle Cell Disease (Hematology), the Scleroderma Vascular Disease Group (Rheumatology) and Pulmonary Vascular/Left Ventricular Study Group (Cardiology). Dr. Farber’s laboratory is investigating the response of the pulmonary vasculature in different etiologies of pulmonary hypertension using genomic and proteomic approaches to identify unique molecules as potential targets for new therapies for pulmonary hypertension associated with sickle cell disease, with scleroderma, and with left ventricular diastolic dysfunction.

Dr. Farber's team is developing a database and registry of sickle cell patients with pulmonary hypertension (see Dr. Elizabeth Klings' faculty profile) as well as a database and registry of scleroderma patients with various forms of pulmonary disease including pulmonary hypertension. They are participating in numerous multi-center clinical trials of new therapies for pulmonary hypertension and have several single-site trials for novel proof of concept therapies for pulmonary hypertension.

2010 Robert Dawson Evans Special Recognition Teaching Award, Boston University School of Medicine

A Phase IV, Prospective, Single-Arm, Open-Label Study to measure Outcomes in Patients with Pulmonary Arterial Hypertension not on active treatment
02/25/2015 - 02/24/2020 (PI)
Bayer HealthCare Pharmaceuticals

A Phase 2, Dose-ranging, Randomized, Double-blind, Placebo Controlled Study of GS-4997 in subjects with Pulmonary Arterial Hypertension
12/22/2014 - 12/21/2019 (PI)
Gilead Sciences, Inc.

A 24-Week Pilot Study to Investigate Changes in Proteomic and Genomic Profiles in Patients with Pulmonary Arterial Hypertension Associated with Scleroderma Treated with Macitentan-PIONEER 2
11/05/2015 - 11/04/2019 (PI)
Actelion Pharmaceuticals, Ltd.

Uptravi® (SelexiPag): tHe usErs dRug rEgistry
09/01/2016 - 08/31/2018 (PI)
Actelion Pharmaceuticals US, Inc.

REPAIR: Right Ventricular Remodeling in Pulmonary Arterial Hypertension
07/15/2015 - 07/14/2018 (PI)
Actelion Pharmaceuticals, Ltd.

A Prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group, 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-ca
06/11/2014 - 06/06/2018 (PI)
Actelion Clinical Operations, Inc.

A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled, Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Sympto
06/01/2012 - 05/31/2017 (PI)

EPOCH Treatment Satisfaction Qualitative Study (EPOCH-TSQS)
03/10/2015 - 03/09/2017 (PI)
Actelion Pharmaceuticals, Ltd.

A multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to psychometrically validate the PAH-SYMPACT instrument
10/17/2013 - 01/01/2017 (PI)
Actelion Pharmaceuticals, Ltd.

A Randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable CTEPH
09/15/2014 - 09/14/2016 (PI)
GlaxoSmithKline, Inc.

Showing 10 of 37 results. Show All Results

Yr Title Project-Sub Proj Pubs
2017 Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension 1R21AR069285-01A1
2015 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-05-7133 25
2014 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-04-7133 25
2013 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-03-7133 25
2012 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-02-7133 25
2011 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 1P50AR060780-01-7133 25
2007 Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome 5U54HL070819-05-2 78
2006 Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens 5R01HL068232-04 1
2006 Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome 5U54HL070819-04-2 78
2005 Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens 5R01HL068232-03 1
Showing 10 of 25 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Farber HW, McDermott S, Witkin AS, Kelly NP, Miloslavsky EM, Stone JR. Case 11-2018: A 48-Year-Old Woman with Recurrent Venous Thromboembolism and Pulmonary Artery Aneurysm. N Engl J Med. 2018 Apr 12; 378(15):1430-1438. PMID: 29641962.
  2. Farber HW, Benza RL. Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials? Am J Respir Crit Care Med. 2018 Apr 01; 197(7):843-845. PMID: 29373796.
  3. Farber HW, Badesch DB, Benza RL, Elliott CG, Frantz RP, McGoon MD, Selej M, Zhao C, Frost AE. Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. J Heart Lung Transplant. 2018 Mar 17. PMID: 29653800.
  4. Benza RL, Farber HW, Frost A, Grünig E, Hoeper MM, Busse D, Meier C, Nikkho S, Ghofrani HA. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant. 2018 Mar 01. PMID: 29580746.
  5. Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. Chest. 2018 Jan 31. PMID: 29355551.
  6. Abston E, Farber H. Pulmonary Cavity From Mycobacterium malmoense in an HIV-Infected Patient: Complicated by Bronchopleural Fistula. Open Forum Infect Dis. 2018 Feb; 5(2):ofy023. PMID: 29450215.
  7. Miller DP, Farber HW. Pulmonary Veno-Occlusive Disease: Welcome to the PAHty (Bostonian for Party). Circulation. 2017 Nov 21; 136(21):2034-2036. PMID: 29158214.
  8. Benza RL, Farber HW, Frost A, Ghofrani HA, Gómez-Sánchez MA, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper MM. REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. J Heart Lung Transplant. 2018 Apr; 37(4):513-519. PMID: 29223470.
  9. Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. J Heart Lung Transplant. 2018 Jun; 37(6):696-705. PMID: 29174533.
  10. Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2018 Mar; 37(3):401-408. PMID: 29096938.
Showing 10 of 209 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 209 publications over 38 distinct years, with a maximum of 15 publications in 2015

Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map

Farber's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department